Omega-3 fatty acids (FA), as a nutrient, has been proven effective in major depressive disorder (MDD), however, the results of monotherapy in perinatal depression (PND) remain unclear. To examine the efficacy and safety of omega-3 fatty acids (FA) monotherapy for perinatal depression (PND) compared with placebo. PubMed, Embase, PsycINFO, MEDLINE, Cochrane Library, and CINAHL were searched from inception up to November 2019. The reference lists of relevant review articles and included studies were also reviewed. Randomized placebo-controlled trials examining the efficacy and safety of omega-3 FA monotherapy in perinatal women with depressive symptoms were included. Pooled standard mean differences (SMD) were calculated and random-effects models were adopted for all analyses. Subgroups analyses and meta-regression were performed to quantify characteristics of the subjects and trials influencing the omega-3 response. In addition, meta-regression was conducted to identify the source of heterogeneity. The study protocol was registered at PROSPERO, CRD42020159542. Eight eligible randomized placebocontrolled trials were included involving 638 participants. There was a significant effect of omega-3 FA on perinatal depression. Omega-3 with higher ratio of EPA/DHA (≥1.5) had significant efficacy both in mild-to-moderate pregnant and postpartum depression with low incidence of side effects. Among the included trials reporting adverse effects, there was no significant difference in incidence of gastrointestinal and neurologic events between the omega-3 and placebo groups. There was no evidence of publication bias. Our findings suggested that omega-3 FA significantly improved depressive symptoms in perinatal women regardless of pregnant or postpartum and well-tolerated. Furthermore, the omega-3 response was linked to higher EPA proportion in omega-3 formula and mild-to-moderate depression.
Sepsis is a life-threatening organ dysfunction caused by a disordered response of the body to infection. 1 Septic shock is a phenomenon relating to sepsis and is a serious disorder involving both the circulatory system and cell metabolism. During septic shock, extremely low blood pressure is observed, and this requires use of a vasoactive drug after adequate volumetric resuscitation has been applied, in order to maintain average blood pressure ≥ 65 mmHg and lactate concentration ≥ 2 mmol/l. Septic shock is the most life-threatening subtype of sepsis, with a mortality rate of 20% to 45%. 2 Fluid resuscitation is a key component of treatments for sepsis and septic shock. Over the past 30 years, many randomized clinical trials (RCTs) and systematic reviews 3-8 that evaluated the therapeutic effects of various fluid resuscitation therapies on sepsis concluded that crystalloid and albumin were the most beneficial therapeutic agents, while use of artificial colloid was associated with a higher death rate and with adverse events. However, few RCTs and systematic reviews have compared the therapeutic effects of crystalloid and albumin regarding septic shock. 9-13 Moreover, the researchers involved in the studies available differed in their conclusions. 14-21 According to the findings from the Enhanced Recovery after Surgery (ERAS) study, 14 albumin does not reduce the mortality rate due to septic shock, whereas the findings from another large RCT called ALBIOS (NCT00707122) 15 concluded that fluid resuscitation using albumin could reduce the mortality rate from septic shock. In 2014, contrary results were reported in a meta-analysis by Patel et al., 16 which found that there was no difference between the effects from albumin and crystalloid treatment, while another meta-analysis by Xu et al. 17 reported that albumin treatment had positive results with regard to reducing the mortality rate among adult patients with septic shock. These studies have shown that it is not yet a foregone conclusion that albumin is superior to crystalloid for reducing the mortality rate in septic shock cases. In 2015, the Lactated Ringer Versus Albumin in Early Sepsis Therapy (RASP) RCT (NCT01337934) 18 specifically compared 4%
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.